Neuroblastoma

Critical Reviews in Oncogenesis
Johannes Hubertus Schulte, Angelika Eggert

Abstract

Neuroblastoma is the most common extracranial solid tumor in children. Since its first description some 150 years ago, its enigmatic clinical presentation has challenged clinicians and fascinated basic researchers. This article presents an overview of the key clinical features of neuroblastoma and current therapeutic approaches. It also highlights how our understanding of sympathoadrenal developmental biology, coupled with transcriptome analyses, next-generation sequencing, and genome-wide association and epigenetic studies, has illuminated critical signal transduction pathways involved in neuroblastoma tumorigenesis and identified therapeutically tractable targets for clinical development.

Citations

Jun 2, 2016·American Society of Clinical Oncology Educational Book·Frank SpelemanTara O Henderson
Jan 13, 2019·The Journal of Pharmacology and Experimental Therapeutics·Carlos Rodríguez-NogalesMaría J Blanco-Prieto
Aug 10, 2018·Cancer Medicine·Ji-Cheng WuHua-Chuan Zheng
Jul 1, 2017·Pediatric Hematology and Oncology·Atif A AhmedMaxine Hetherington
Jun 29, 2016·Oncotarget·Francesco Maria CalabreseMario Capasso
Jan 24, 2018·Cancer Discovery·David S RickmanMartin Eilers
Jan 7, 2021·Cancer Metastasis Reviews·Irfete S Fetahu, Sabine Taschner-Mandl
Jan 22, 2021·Molecular and Cellular Biochemistry·Ming ChenBin Zhu
Jan 27, 2019·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Juliano J CerciThomas N Pascual
Aug 28, 2021·Journal of Personalized Medicine·Annabell SzymanskyJohannes H Schulte
Sep 4, 2021·Journal of Immunological Methods·Gislaine FurlanettoMariana Bohns Michalowski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.